Zobrazeno 1 - 10
of 329
pro vyhledávání: ''
Autor:
Pingfu Fu, Monaliben Patel, John J. Pink, Tithi Biswas, Mitchell Machtay, Shufen Cao, Charles A Kunos, Debora S. Bruno, Stanton L. Gerson, David L. Bajor, Nancy L. Oleinick, Shakun Malik, Afshin Dowlati
Publikováno v:
Clin Cancer Res
Purpose: TRC102, a small-molecule base-excision repair inhibitor, potentiates the cytotoxicity of pemetrexed and reverses resistance by binding to chemotherapy-induced abasic sites in DNA. We conducted a phase I clinical trial combining pemetrexed an
Autor:
Cristiana Sessa, Monia Guidi, Laura Moser, Eleftherios P. Samartzis, Mariarosa Pascale, Ilaria Colombo, Tatiana Terrot, Milo Frattini, Simone Brandt, Anastasios Stathis, Sheila Gaggetta, Sofia Genta, Federica Martorana
Publikováno v:
Clinical Cancer Research. 27:5012-5019
Purpose: This phase I study evaluated safety, tolerability, pharmacokinetics, and preliminary activity of the PI3K/mTORC1/2 dual inhibitor gedatolisib combined with carboplatin and paclitaxel. Patients and Methods: Patients with advanced solid tumors
Autor:
Konstantin Penkov, Taofeek K. Owonikoko, Peter M. Ellis, Bruce A. Bach, Anne Sibille, Vasudha Sehgal, Choon Hee Son, Lei He, Jaimee Glasgow, Harry J.M. Groen, Junya Fujimoto, Patricia M. de Groot, Kingston Kang, Martin Dunbar, Lauren Averett Byers, Steven J. M. Gans, Dmitry Bentsion
Publikováno v:
Clinical Cancer Research, 27(14), 3884-3895. AMER ASSOC CANCER RESEARCH
Purpose: This study investigated the efficacy and safety of oral PARP inhibitor veliparib, plus carboplatin and etoposide in patients with treatment-naïve, extensive-stage small cell lung cancer (ED-SCLC). Patients and Methods: Patients were randomi
Autor:
Garry Ceccon, Philipp Lohmann, Erkan Celik, Christian Baues, Norbert Galldiks, Caroline Tscherpel, E K Bauer, Gereon R. Fink, Christoph Kabbasch, Gabriele Stoffels, Gerrit H. Gielen, Christina Schaub, Jan-Michael Werner, Johannes Weller, Ulrich Herrlinger, Karl-Josef Langen, Simone Marnitz, Niklas Schäfer
Publikováno v:
Clinical cancer research 27(13), 3704-3713 (2021). doi:10.1158/1078-0432.CCR-21-0471
Purpose: The CeTeG/NOA-09 phase III trial demonstrated a significant survival benefit of lomustine–temozolomide chemoradiation in patients with newly diagnosed glioblastoma with methylated O6-methylguanine-DNA methyltransferase (MGMT) promoter. Fol
Autor:
Jordi Rodon, Joann Lim, Elizabeth A. Sumner, Hira Zain, Di Nguyen, Jack P. Higgins, Vivek Subbiah, Funda Meric-Bernstam, Eric T Williams, Coline Agnes Couillault, Siqing Fu, Timothy A. Yap, Kimal Rajapakshe, Aparna Hegde, Sarina Anne Piha-Paul, Shubham Pant, Michael A. Curran, Priya Bhosale, Priyamvada Jayaprakash, David S. Hong, Thomas F. Wilson, Daniel D. Karp, Ecaterina Ileana Dumbrava, Ly M. Nguyen, Cristian Coarfa
Publikováno v:
Clin Cancer Res
Purpose: As hypoxia can mediate resistance to immunotherapy, we investigated the safety, tolerability, and efficacy of combining evofosfamide, a prodrug that alleviates hypoxia, with ipilimumab, an immune checkpoint inhibitor, in immunologically “c
Autor:
Phillip L. Palmbos, Przemyslaw Twardowski, Vivek K. Arora, Alicia K. Morgans, Dan R. Robinson, Karen E. Knudsen, Matthew S. Davenport, Maha Hussain, Neeraj Agarwal, Javed Siddiqui, Emmanuel S. Antonarakis, Jon A. Jacobson, Stephanie Daignault-Newton, Scott A. Tomlins, Wm. Kevin Kelly, Arul M. Chinnaiyan
Publikováno v:
Clin Cancer Res
Purpose: Palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, blocks proliferation in a RB and cyclin D–dependent manner in preclinical prostate cancer models. We hypothesized that cotargeting androgen receptor and cell cycle with palbocicli
Autor:
Guanghui Gao, Zhe-Hai Wang, Jifeng Feng, Meijuan Huang, Xinmin Yu, Zhihua Liu, Caicun Zhou, Lihong Wu, Yina Wang, Ying Cheng, Jun Zhao, Yuan Chen, Zhiyong Ma, Weixia Li, Xiaoyan Lin, Shengxiang Ren, Kangsheng Gu, R. Guo, Jun Zhang, Quan Ren Wang, Xinfeng Yang, Gongyan Chen, Yu Yao, Jianxing He, Jianhua Chen, Jianhua Shi
Publikováno v:
Clinical Cancer Research. 27:1296-1304
Purpose: Our preclinical work suggests that appropriate angiogenesis inhibition could potentiate PD-1/PD-L1 blockade via alleviating hypoxia, increasing infiltration of CD8+ T cells and reducing recruitment of tumor-associated macrophages. We hereby
Autor:
Abdulkhaliq Alsaadi, Christina Fotopoulou, Eric O. Aboagye, Jennifer Ploski, Mara Artibani, Paula Cunnea, Sarah P. Blagden, Ashwag Albukhari, Oloruntoba I. Osagie, Sunanda Dhar, Joanna Hester, Leticia Campo, Laura Santana Gonzalez, Katherine Nixon, Zhiyuan Hu, Christopher Yau, Haonan Lu, Nina Wietek, Ahmed Ashour Ahmed, Stephen Damato, Zhe Zhong
Publikováno v:
Clinical cancer research, 27(5), 1570-1579. American Association for Cancer Research Inc.
Purpose: Using RNA sequencing, we recently developed the 52-gene–based Oxford classifier of carcinoma of the ovary (Oxford Classic, OxC) for molecular stratification of serous ovarian cancers (SOCs) based on the molecular profiles of their cell of
Autor:
Massimo Cristofanilli, Kalliopi P. Siziopikou, Qiang Zhang, Lisa Flaum, Andrew M. Davis, Lorenzo Gerratana, Ami N. Shah, Amir Behdad, Leonidas C. Platanias, Neelima Katam, Saya Jacob, William J. Gradishar, Aditya Bardia, Firas Wehbe, Marko Velimirovic
Publikováno v:
Clinical Cancer Research. 27:1361-1370
Purpose: Circulating tumor DNA (ctDNA) is a promising tool for noninvasive longitudinal monitoring of genomic alterations. We analyzed serial ctDNA to characterize genomic evolution in progressive metastatic breast cancer. Experimental Design: This w
Autor:
Hans-Peter Sinn, Christian Schem, Frederick Klauschen, Karsten Weber, Andreas Schneeweiss, Elmar Stickeler, Marion von Mackelenbergh, Dirk Michael Zahm, Sibylle Loibl, Bruno Valentin Sinn, Denise Treue, Claus Hanusch, Frederik Marmé, Clemens Becker, Michael Untch, Jenny Furlanetto, Carsten Denkert, Thomas Karn, Nicole Burchardi, Peter A. Fasching, Wolfgang D. Schmitt, Volkmar Müller
Publikováno v:
Clinical Cancer Research. 27:2584-2591
Purpose: We evaluated mRNA signatures to predict response to neoadjuvant PD-L1 inhibition in combination with chemotherapy in early triple-negative breast cancer. Experimental Design: Targeted mRNA sequencing of 2,559 transcripts was performed in for